You've made some fair points in the past. But now you're just arguing to support your position.
Comparing WARMTH and LuPIN seems justified, based on the data presented in the announcement. There seems little basis to argue that the WARMTH patients had significantly more advanced disease than the LuPIN patients - the opposite appears true. So it is not a stretch to compare the outcomes of the two patient groups.
But oncology is not my field.
Ann: New Independent Trial Data Supports Potential of Veyonda, page-11
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $21.04M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 67034 | 7.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.8¢ | 101131 | 1 |
View Market Depth
| Last trade - 11.56am 19/07/2024 (20 minute delay) ? |
| NOX (ASX) Chart |
Day chart unavailable